 |
|
|
|
 |
|
|
| Article 1 to 10 out of 52 concerning F. Hoffmann-La Roche AG
|
-
454 sequencing at the forefront of bone marrow and stem cell therapy research
(07/01/2008)
Roche Genome Sequencer FLX System creates new opportunities for HLA research at the Blood Centre Linz, Austria
The Blood Centre Linz, Austria has purchased a Genome Sequencer FLX System from Roche, for use in research on rejection reactions in Bone Marrow and Stem Cell transplantation. Using conventional Sanger sequencing it can take weeks to analyse large ...
-
ThromboGenics and BioInvent announce a strategic alliance with Roche for TB-403, a novel anti-cancer antibody
(06/19/2008)
ThromboGenics NV and BioInvent International AB announced that they have entered into a license agreement with Roche for their jointly developed anti-cancer agent TB-403. TB-403 is a novel monoclonal antibody which blocks Placental Growth Factor ...
-
Roche Signs Exclusive Distribution Deal with DxS for K-RAS and EGFR Cancer Mutation Tests
(06/04/2008)
Tests identify genetic mutations that can affect patient response to certain cancer drugs
Roche and DxS Ltd. have signed an exclusive distribution agreement for the DxS TheraScreen K-RAS Mutation Test and TheraScreen EGFR 29 Mutation Test. The tests are intended, when considered with other clinically relevant factors, to aid doctors in ...
-
Roche NimbleGen and Affymetrix Expand Licensing Agreement
(03/17/2008)
Roche NimbleGen Inc., a company of Roche Applied Science, and Affymetrix Inc. announced that they have expanded the terms of the license to a number of Affymetrix patents originally granted in October 2006. The expanded license now provides certain ...
-
Abbott to Collaborate With Genentech, Roche and OSI on Molecular Test for Lung Cancer Therapy Response
(03/11/2008)
Abbott's FISH Technology Provides Analytical Tool with Potential to Assess Clinical Response to Lung Cancer Treatment in Patients with Non-Small-Cell Lung Cancer
Abbott announced that its molecular diagnostics business has entered into an agreement with Genentech, Inc., F. Hoffmann-La Roche Ltd. and OSI Pharmaceuticals, Inc. to develop a gene test to potentially assess the clinical benefit of Tarceva(R) ...
-
New Analytica Research Prize from Roche and the GBM Strengthens Research in Germany
(02/25/2008)
Roche and the German Society for Biochemistry and Molecular Biology (GBM) are reorienting their joint research prize this year. Funded by Roche to the value of 50,000 euros, the prize is awarded by the GBM every two years to one or two scientists. ...
-
Transplantation Safety: New Virus Detected Using Genome Sequencer Technology
(02/11/2008)
454 Life Sciences, a part of Roche Applied Science, announced that researchers at Columbia University and Victorian Infectious Disease Reference Laboratory have discovered a new virus that was responsible for the deaths of three transplant ...
-
Researchers use the Genome Sequencer System to sequence and assemble the Pinot Noir Genome
(01/03/2008)
454 Life Sciences, a part of Roche Applied Science, announced that researchers from the Istituto Agrario San Michele all'Adige and Myriad Genetics have used the company's first generation instrument, the Genome Sequencer 20 System, to sequence and ...
-
Roche: reduce the need for mastectomies in women with inflammatory HER2-positive breast cancer
(09/28/2007)
New data show that the addition of Herceptin (trastuzumab) to chemotherapy prior to breast cancer surgery (neoadjuvant therapy) completely eradicates tumours in nearly three times as many women with inflammatory HER2-positive breast cancer compared ...
-
Researchers Identify Virus Possibly Responsible for Declining Honeybee Population
(09/10/2007)
454 Life Sciences, a Roche company, announced that researchers at Columbia University, in collaboration with 454, have identified a virus implicated in the deaths of 2.4 million honeybee colonies - tens of billions of bees - using the company's ...
Additional information
F. Hoffmann-La Roche AG
Basel, Switzerland
Company
|
|
|
|
|
|
Top
